Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Nektaria Papadopoulou-Marketou
 -- 3123 2023-06-02 10:43:14 |
2 Format correct
Wendy Huang
Meta information modification 3123 2023-06-05 10:13:49 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Papadopoulou-Marketou, N.; Papageorgiou, A.; Chrousos, G.P. Stress-Induced Osteosarcopenic Obesity. Encyclopedia. Available online: https://encyclopedia.pub/entry/45131 (accessed on 01 July 2024).
Papadopoulou-Marketou N, Papageorgiou A, Chrousos GP. Stress-Induced Osteosarcopenic Obesity. Encyclopedia. Available at: https://encyclopedia.pub/entry/45131. Accessed July 01, 2024.
Papadopoulou-Marketou, Nektaria, Anna Papageorgiou, George P. Chrousos. "Stress-Induced Osteosarcopenic Obesity" Encyclopedia, https://encyclopedia.pub/entry/45131 (accessed July 01, 2024).
Papadopoulou-Marketou, N., Papageorgiou, A., & Chrousos, G.P. (2023, June 02). Stress-Induced Osteosarcopenic Obesity. In Encyclopedia. https://encyclopedia.pub/entry/45131
Papadopoulou-Marketou, Nektaria, et al. "Stress-Induced Osteosarcopenic Obesity." Encyclopedia. Web. 02 June, 2023.
Stress-Induced Osteosarcopenic Obesity
Edit
This entry is adapted from the peer-reviewed paper 10.3390/endocrines4020029

Osteosarcopenic obesity (OSO), otherwise known as “osteosarcopenic adiposity”, is a syndrome which clinical phenotype combines impairments in the structure and function of a patient’s bones, skeletal muscles, and adipose tissue. The etymology of the first term originates from three Greek words (osteo- meaning bone-, sarco- meaning flesh, and penia- meaning deficiency). In contrast, the second term has a Latin origin. Chronic stress, i.e., prolonged impairment of homeostasis, results in the coexistence of bone loss (osteoporosis); sarcopenia/dynapenia (decreased muscle performance); and increased adiposity, either as overt, BMI-defined overweight/obesity or because of tissue accumulation and organ infiltration with fat (liver, skeletal muscle, and bone). This condition is becoming more prevalent in aging populations.

stress osteoporosis sarcopenia obesity

1. Etiology and Pathophysiology

The prevalence of osteosarcopenic obesity in community-dwelling adults has been reported to be 10.7% [1]. Several risk factors have been associated with stress-induced osteopenia or osteoporosis, sarcopenia, and obesity All these factors may interconnect and lead to disease.
Chronic stress and the inflammation with which it is associated contribute to OSO and several related pathological phenomena [2][3], depending on an individual’s genetic and epigenetic background, as distinct pathologies.
Recent research suggests that in parallel with an increased BMI, an alteration of body composition is seen, with an increase in fat mass from 10 to 25 percent in men and from 20 to 35 percent in women, and a decrease in muscle mass from 50 to less than 40% in men and from 35 to less than 30% in women [4]. This shift in body composition linked to obesity represents an additional risk factor for insulin resistance, sarcopenia, osteoporosis, and cardiometabolic consequences [4]. In addition, mesenchymal stem cells may be diverted from the production of bone and muscle toward adipose tissue [5].
To confront the state of dyshomeostasis, multiple processes occur in the body, resulting in the activation of the sympathetic nervous system (SNS) and the hypothalamic–pituitary–adrenal axis (HPA) [6].
These systems release chemicals to help restore balance, such as catecholamines released to increase heart rate and blood pressure, allowing the body to address the fight against the trigger of change [7]. These processes are pivotal in the survival and adaptation of the human organism [7].
However, chronic cacostasis has been linked to pathological consequences in the endocrine, immune, nervous, and cardiovascular systems and one’s body composition [8]. In addition, prolonged stress is a risk factor for developing several physical and psychiatric disorders [8]. Stress-related diseases may be cardiovascular, metabolic, psychiatric, neurodegenerative diseases, or cancer [9].

1.1. Stress and Inflammation

Given its subclinical nature, low-grade chronic inflammation is challenging to diagnose [10]. It is defined by the presence of an increased number of circulating pro-inflammatory cytokines and an unsubsiding presence of excess immune cells in one’s circulatory system [10]. In addition, due to the extensive adverse effects, subclinical inflammation has a remarkable impact on the body’s metabolic processes [11].
Several lines of evidence have shown that metabolic syndrome and obesity are associated with oxidative stress. For example, impaired high-density lipoprotein (HDL)-enabled antioxidative mechanism, increased lipid peroxidation, carbonylation of cellular proteins, and NADPH oxidase activity are associated with obesity, leading to enhanced ROS formation and advanced mitochondrial oxidative products [12]. In addition, recent studies found that alterations in peripheral interleukin-6 circadian rhythm, as a sequel of combat deployment, were associated with cases of posttraumatic stress [10][13].

1.2. Endocrine Factors

Chronically elevated cortisol secretion, low-grade chronic inflammation, and the associated insulin resistance synergistically impair bone, muscle, and adipose tissue functions [14]. In the presence of glucocorticoids, mesenchymal stem cells involved in the production of bone, muscle, and adipose tissue show preferential differentiation into adipose tissue over bone or muscle tissue [15]. Excess adiposity, primarily abdominal or visceral adiposity, is associated with the secretion of inflammatory cytokines and other mediators, which appear to participate in a “positive feedback loop” between inflammation and excess body fat. Thus, progressively increasing fat accumulation is associated with gradually increasing secretion of inflammatory molecules, worsening insulin sensitivity, and increasing cortisol secretion, with these changes leading to further adiposity [2]. Modern-day Western lifestyles that are more passive and nutritionally deficient and more fast-paced and stressful than our evolutionary paradigms may lead to pathologies, including OSO [16][17].
Adipocytes produce adipokines; by secreting pro-inflammatory adipokines, adipocytes contribute to the inflammatory status of the human organism [18].
Indeed, bodyweight gain may play a key role in inducing OSO. An adipokine, leptin, acts as an afferent signal in a negative feedback loop, controlling adiposity and body weight by suppressing food intake and stimulating the basal metabolic rate. Although obese individuals secrete large amounts of circulating leptin, their central nervous system is typically insensitive to leptin presence, which is called leptin resistance [19]. Leptin resistance may reduce fatty acid (FA) oxidation in muscles, followed by hepatic, myosceletal, and heart fat deposition, thereby decreasing muscle quality in older obese people [19]. Another adipokine, adiponectin, is an anti-inflammatory, insulin-sensitizing peptide that is negatively associated with muscle mass because of its inability to control NF-kB [20]. Another endogenous peptide secreted by adipocytes and induced by muscle contraction is apelin, which production declines with age through several pathways.
An inflammatory state is causative in insulin resistance and promotes skeletal muscle catabolism. Additionally, hypertrophic adipocytes increase the production of free fatty acids, which accumulate ectopically between muscle fibers and inside other non-adipose tissues in the form of triacylglycerol. They cause mitochondrial dysfunction, beta-oxidation of fatty acids, and increased production of reactive oxygen species. In addition, due to the cell saturation of triacylglycerol, they produce toxic reactive lipid species and stimulate apoptosis. These reactive lipids may accumulate in skeletal muscles, contributing to the development of sarcopenia [21][22].
Earlier studies suggested that myostatin, irisin, and osteocalcin mediate the crosstalk between muscles and bones. However, the role of these endocrine factors in the pathogenesis of OSO has not been fully understood. Research data showed that muscle loss in older people may occur through increased levels of myostatin, which is well established for its overexpression in inducing protein degradation in muscles along with inhibiting osteoblastic differentiation in bones; myostatin is a negative regulator of muscle mass that causes muscle atrophy, and decreased concentrations of myosin, the major muscle motor protein, contribute to decreased muscle function [23].
The pathogenic interrelations between adipose tissues and muscles are also crucial in sarcopenia. Myokines are specific peptides secreted by skeletal muscles that mediate some of the known positive effects of physical exercise. Myokines may affect myocytes and immune cells because of autocrine and/or paracrine actions and cells such as adipocytes and hepatocytes via endocrine effects [21]. IL-6 is the most well-studied myokine. Exercise may enhance IL-6 secretion from muscles and increases plasma IL-6 levels up to 100-fold [21]. In addition, the myokine irisin, which is produced during exercise, plays a significant role in controlling fat gain by mediating the trans-differentiation of brown into white adipose tissue, activating non-shivering thermogenesis, and inducing myocyte differentiation and growth via increases in the expression and secretion of insulin-like growth factor 1 (IGF-1), which promotes osteoblastogenesis and myogenesis, along with reducing adipogenesis [24].
Less physical activity with aging may be associated with a decline in muscle mass and irisin production, which leads to an increased adipose tissue mass and, thus, sarcopenic obesity. Furthermore, a recent experimental study showed that irisin stimulates cortical bone mass and bone strength in mice by increasing osteoblastic bone formation, up-regulating pro-osteoblastic genes, and decreasing osteoblast inhibitors [25]. Therefore, reduced irisin production may lead to OSO [24][25]. In addition, immobilization is another cause of the maximum shortening velocity of single muscle fibers [26].

2. Purines

The physiological role of ATP at the skeletal neuromuscular junction has been previously reported. Extracellular nucleotides may act as modulators of bone cell differentiation, function, and survival [27]. In the extracellular space, ATP is hydrolyzed into adenosine by one or more ectonucleotidases in human primary osteoblast cells (HPOC), and nucleoside is the end-product of the cascade [28]. Adenosine accumulates in the extracellular area in response to metabolic or oxidative stress, tissue injury, hypoxia, or inflammation. Purinergic signaling has been implicated in bone since extracellular ATP may disturb bone formation while promoting bone resorption. Still, it also has a crucial role in modulating osteal cells’ differentiation, function, and survival after its physiological secretion in response to mechanical stress [29]. ATP has also been suggested as an endogenous inhibitor of bone mineralization by blocking the mineralization of collagenous matrix [30]. Purinergic signaling via P2 receptors can interact with other intracellular pathways to regulate osteoblast function.
Moreover, ATP has been found to stimulate human osteoclast activity indirectly by inducing upregulation of osteoblast-expressed RANKL via P2X7 receptors [31]. The P2X7 receptor gene, P2RX7, is located on chromosome 12q24.31 and is characterized by numerous polymorphisms [32]. The purinergic P2X7 receptor plays a vital role in regulating osteoblast and osteoclast activity, and every change in receptor function may be reflected in bone mass [33]. The Danish Osteoporosis Prevention Study studied 1694 women who were followed for 10 years and genotyped for 12 functional P2X7 receptor variants. Increased bone loss with fractures was associated with Arg307Gln amino acid substitution, and heterozygous individuals for this polymorphism had a 40% increased rate of bone loss. Low-risk alleles were linked to a low rate of bone loss, and high-risk alleles were associated with increased bone loss [33]. Among the P2 receptor subtypes expressed by bone cells, the P2X7 receptor has been correlated with the treatment of osteoporosis. This receptor has been implicated in regulating the release of inflammatory cytokines IL-6, TNF-α, and plasminogen activator inhibitor-1, at least in part via inflammasome activation [34]. In addition, endogenously released adenosine, which signals via four adenosine receptor subtypes acting on G-protein-coupled receptors, A1, A2A, A2B, and A3, on osteoclasts and their precursor cells, acts as a mediator on bone turnover and trans-differentiation of osteoblasts to adipocytes, showing its key role in the pathogenesis of osteoporosis. The most abundant A2B receptor in bone marrow MSCs seems to have a consistent role in cell differentiation, which may be balanced through the relative strength of A1 or A2A receptor, thus determining whether osteoblasts are driven into proliferation or differentiation [35].
Moreover, A1 receptor has been associated with the lipogenic activity of adipocytes, and A1R is also implicated in adipogenesis and leptin production. A1R regulates lipolysis and serum-free fatty acid levels, playing a crucial role in the pathogenesis of insulin resistance, diabetes, and cardiovascular diseases by controlling the proliferation and regeneration of β cells in inflammatory microenvironments [36]; in addition, it activates lipolysis and the thermogenic program in brown and white human adipocytes [36]. Additionally, preclinical trials suggest that pharmacological manipulation of the purinergic cascade in adipocytes and other adipose tissue cells may be used to treat obesity and type 2 diabetes [37]. Purines act synergistically with hormones (e.g., PTH), playing a fundamental role in mesenchymal stem cell proliferation and differentiation (adipogenesis, myogenesis, and osteogenesis) [38].
Both nutritional stress and the genetic model of obesity are linked to an increased expression of P2X7 that is correlated with increased macrophage infiltration within adipose tissues and increased expressions of CD39 and CD73. Purinergic signaling cascade in adipocytes and other cellular players of fatty tissues may be a valuable target for treating obesity and metabolic disorders. Further experimental studies showed that P2X7R stimulation directs the differentiation of MSCs toward the osteoblast lineage rather than toward adipocytes. In addition, animal studies found that ATP and BzATP reduce leptin mRNA levels and inhibit insulin-induced leptin secretion. Furthermore, adenosine has been implicated in inflammation and sustaining IL-1β production in metabolically unhealthy obese individuals; moreover, its receptor expression is correlated with increased body mass index [39]. However, the exact pathophysiological pathways between purine metabolism and OSO remain unclear and offer an exciting field for further research.

2.1. Vitamin D

Since 1969, when Haussler described Vitamin D and its receptor (VDR) and confirmed its presence in various tissues, many researchers have focused on the mechanistic link between vitamin D and the occurrence of various diseases, such as obesity, a chronic, low-grade inflammatory state that leads to impaired metabolic processes in adipose and lean tissues; the pathogenesis of insulin resistance; metabolic syndrome; type 2 diabetes mellitus; and cancer prevention [40][41][42]. The presence of VDR has been reported in skeletal muscle tissues [43]; therefore, numerous studies have focused on musculoskeletal disorders and the mechanical properties of vitamin D function. In adults and older adults, moderate vitamin D deficiency is often associated with increased serum parathormone (PTH) concentration, leading to high bone turnover and decreased BMD. In the MORE study, postmenopausal women with vitamin D deficiency had significantly higher serum PTH, more elevated serum alkaline phosphatase, and lower BMD of the trochanter compared with those with adequate 25OHD levels [44]. A significant positive effect of vitamin D supplementation on global muscle strength in older adults was previously shown, but no impact on lean mass was reported [45]. Additionally, vitamin D supplements increase lower limb muscle strength in athletes [46].
Moreover, vitamin D deficiency has been linked with an increased risk of falls, and past studies have shown benefits after vitamin D and calcium supplementation in elderly recurrent fallers, mainly during winter. A recent meta-analysis reported that when vitamin D was supplemented with calcium.there was a significant reduction in fall incidence and fracture rates [47]. However, high annual or monthly single oral doses of vitamin D increased the risk of falling in a U-shaped model. The authors suggested that the lower value of fall rates occurred in the dose range of 1600 to 3200 IU/d [48]. The association between obesity and vitamin D deficiency has been previously documented [49]. A population-based prospective cohort study with 1501 participants from Norway reported a negative correlation between season-standardized serum 25(OH)D level and risk of clinical weight gain [50]. 

2.2. Genetic and Epigenetic Factors

Family history is a well-established risk factor for osteoporosis, sarcopenia, and obesity; genotype is, in fact, a significant influencer of altered energy balance.
The hypothalamus plays a critical role in energy expenditure and balance. Recent studies suggested that predisposing genetic traits related to appetite and satiety may be linked to behavioral traits through appetitive neural pathways influencing control over overeating or eating in response to negative emotions [51]. Additionally, the hippocampus and the rest of the limbic system have been associated with cognition, memory, emotion, and control of BMI [51].
Monogenic or oligogenic autosomal or X-linked patterns of inheritance have been described; however, obesity is primarily polygenic and is a result of multiple gene defects interacting with the environment [52].
Homozygous mutation in the leptin (LEP) gene and loss-of-function mutations in SH2B1 (SH2B adaptor protein 1, a key regulator of leptin signaling by both stimulating Janus kinase 2 (JAK2) activity and assembling a JAK2/IRS1/2 signaling complex) are associated with rapid weight gain within the first years of life, severe hyperphagia, and behavioral problems [52]. Other homozygous/compound heterozygous loss-of-function mutations in monogenic obesity genes in the leptin/melanocortin pathway or heterozygous loss-of-function mutations in POMC, including loss-of-function missense mutation in β-MSH, partial loss-of-function heterozygous mutations in PCSK1, heterozygous loss-of-function coding mutations in the melanocortin 3 receptor (MC3R) gene, and heterozygous mutations in melanocortin receptor accessory protein 2 (MRAP2), have all been associated with either childhood or adult obesity. As with obesity, osteoporosis and sarcopenia have a vital genetic component, with heritability ranging over 50%.
On the other hand, mutations or polymorphisms of the gene family 210 member A (FAM210A), growth/differentiation factor 8 (GDF8) (also known as myostatin), methyltransferase-like 21C (METTL21C), and sterol regulatory element-binding transcription factor 1/target of myb1-like 2 (SREBF1/TOM1L2) have been linked to genetic predisposition for sarcopenia and osteoporosis [53]. Moreover, smoking-related postmenopausal osteoporosis has been recently associated with mutations in HNRNPC, PFDN2, PSMC5, RPS16, TCEB2, and UBE2V2 genes [54]. Recently, several genome-wide association studies (GWASs) and meta-analyses have focused on genetic alterations associated with BMD in osteoporosis. Among them, the most featured loci are SMOC1, CLDN14, ZBTB40, GPR177, FGFRL1, MEPE, MEF2C, ESR1, SHFM1, WNT16, OPG, SOX6, LRP5, AKAP11, and FOXL1 [55]. Polymorphisms of MTHFR, ACTN3, NRF2, VDR FokI, ADRB2, and NPAS4 loci have been linked with sarcopenia in older adults. A recent study suggested a genetic risk score regarding sarcopenia onset [56]. Moreover, new data were recently reported regarding 10 genes (CFB, CXCL2, HSD11B1, IGF1, IL6, NTN1, PCSK1, PPARGC1A, SOD2, and TF) that were associated with osteoporosis, sarcopenia, and obesity-induced diabetes [57].

2.3. Aging

The skin has a crucial role in producing the prohormone vitamin D and transforming it into inactive metabolites [38]. It is well documented that advancing age reduces the skin’s capability to synthesize pre-vitamin D3 [58]. It has been reported that the concentration of the precursor of vitamin D3 in the skin, 7-dehydrocholesterol(7-DHC), declines by about 50% from age 20 to 80. Moreover, another study found that older age was a significant predictor of decreased VDR expression [59]. Therefore, vitamin D deficiency, taking into consideration the above-described vitamin D actions, could play a significant synergistic role in OSO following advancing age.
Several cellular changes occur in sarcopenic muscles, including decreased size and reduction in several mostly type II myofibers. Aging promotes the transition of muscle fibers from type II to type I, along with intramuscular and intermuscular fat infiltration (myosteatosis). Cross-sectional studies of single muscle fibers from healthy people found a reduction in muscle fiber quality in fibers expressing type I or IIA myosin heavy chain and, over time, a significant decrease in single muscle fiber peak power [23]. Other biological effects of aging are maximum unloaded shortening velocity, decreased elasticity, and greater stiffness per force unit in older men [23]. Subclinical inflammation also plays an essential role in high muscle catabolism in older people [23]. A decline in satellite cells associated with type IIA fibers suggests a decrease in the regenerative capacity of muscle fibers and a failure to recompense the loss of fibers [23]. The loss of lean mass in sarcopenia is associated with increased accumulated adipose tissue in muscle, increasing myosteatosis with advancing age [60].
Mesenchymal stem cells (MSCs) can differentiate into bone cells, but in elderly individuals, these cells are decreased, resulting in osteoporosis. Adenine and uracil nucleotides are important local regulators of osteogenic differentiation of MSCs in bone marrow [61]. In addition, previous studies showed that cysteine (C)-X-C chemokine receptor-4 (CXCR4), the primary transmembrane receptor for stromal cell-derived factor-1, has decreased expression with aging in bone marrow-derived mesenchymal stromal stem cells (BMSCs), and this CXCR4-deficiency alters the osteogenic differentiation potency of older BMSCs. Recent studies using osteoprogenitor cell lines, animal models, and non-modified MSCs from postmenopausal women have focused on the purinergic signaling pathway and specific targets to regenerate the ability of aged MSCs to differentiate into active osteoblasts [61].
In addition, aged satellite cells, considered the key elements of sarcopenia by altering the regeneration of myofibers, have been shown to translocate across the basal lamina following age-dependent extracellular wall stiffness [62]. Furthermore, decreased muscle fiber vascularization is associated with impaired regulation of satellite cells in older adults [62]. With advanced age, the multiplication of bone marrow stem cells is diminished. Several studies indicated that both sarcopenia and osteoporosis are associated with stem cell senescence and exhaustion along with implicated pathophysiological mechanisms, such as impaired telomere and high levels of reactive oxygen species [53].

References

  1. Kolbaşı, E.N.; Demirdağ, F. Prevalence of osteosarcopenic obesity in community-dwelling older adults: A cross-sectional retrospective study. Arch. Osteoporos. 2020, 15, 1–9.
  2. Ilich, J.Z.; Kelly, O.J.; Kim, Y.; Spicer, M.T. Low-grade chronic inflammation perpetuated by modern diet as a promoter of obesity and osteoporosis. In Arhiv za Higijenu Rada i Toksikologiju; Institute for Medical Research and Occupational Health: Zagreb, Croatia, 2014; Volume 65, pp. 139–148.
  3. Ilich, J.Z.; Kelly, O.J.; Inglis, J.E.; Panton, L.B.; Duque, G.; Ormsbee, M.J. Interrelationship among muscle, fat, and bone: Connecting the dots on cellular, hormonal, and whole body levels. In Ageing Research Reviews; Elsevier Ireland Ltd.: Amsterdam, The Netherlands, 2014; Volume 15, pp. 51–60.
  4. Eaton, S.B.; Eaton, S.B. Physical Inactivity, Obesity, and Type 2 Diabetes: An Evolutionary Perspective. In Research Quarterly for Exercise and Sport; Routledge: Abingdon, UK, 2017; Volume 88, pp. 1–8.
  5. Caplan, A.I. Mesenchymal stem cells: Time to change the name! Stem Cells Transl. Med. 2017, 6, 1445–1451.
  6. Foley, P.; Kirschbaum, C. Human hypothalamus-pituitary-adrenal axis responses to acute psychosocial stress in laboratory settings. Neurosci. Biobehav. Rev. 2010, 35, 91–96.
  7. Chrousos, G.P. Stress and disorders of the stress system. Nat. Rev. Endocrinol. 2009, 5, 374–381.
  8. Tamashiro, K.L.K.; Hegeman, M.A.; Nguyen, M.M.N.; Melhorn, S.J.; Ma, L.Y.; Woods, S.C.; Sakai, R.R. Dynamic body weight and body composition changes in response to subordination stress. Physiol. Behav. 2007, 91, 440–448.
  9. Cohen, S.; Janicki-Deverts, D.; Miller, G.E. Psychological stress and disease. JAMA 2007, 298, 1685–1687.
  10. Agorastos, A.; Hauger, R.L.; Barkauskas, D.A.; Lerman, I.R.; Moeller-Bertram, T.; Snijders, C.; Haji, U.; Patel, P.M.; Geracioti, T.D.; Chrousos, G.P.; et al. Relations of combat stress and posttraumatic stress disorder to 24-h plasma and cerebrospinal fluid interleukin-6 levels and circadian rhythmicity. Psychoneuroendocrinology 2019, 100, 237–245.
  11. Hotamisligil, G.S. Inflammation and metabolic disorders. Nature 2006, 444, 860–867.
  12. Rani, V.; Deep, G.; Singh, R.K.; Palle, K.; Yadav, U.C.S. Oxidative stress and metabolic disorders: Pathogenesis and therapeutic strategies. Life Sci. 2016, 148, 183–193.
  13. Chrousos, G.P. Stress, chronic inflammation, and emotional and physical well-being: Concurrent effects and chronic sequelae. J. Allergy Clin. Immunol. 2000, 106 (Suppl. 5), S275–S291.
  14. Lecka-Czernik, B. Diabetes, bone and glucose-lowering agents: Basic biology. Diabetologia 2017, 60, 1163–1169.
  15. Wu, C.L.; Diekman, B.O.; Jain, D.; Guilak, F. Diet-induced obesity alters the differentiation potential of stem cells isolated from bone marrow, adipose tissue and infrapatellar fat pad: The effects of free fatty acids. Int. J. Obes. 2013, 37, 1079–1087.
  16. Wellen, K.E.; Hotamisligil, G.S. Inflammation, stress, and diabetes. J. Clin. Investig. 2005, 115, 1111–1119.
  17. Milutinović, D.V.; MacUt, D.; Božić, I.; Nestorov, J.; Damjanović, S.; Matić, G. Hypothalamic-pituitary-adrenocortical axis hypersensitivity and glucocorticoid receptor expression and function in women with polycystic ovary syndrome. Exp. Clin. Endocrinol. Diabetes 2011, 119, 636–643.
  18. Cruz-Jentoft, A.J.; Bahat, G.; Bauer, J.; Boirie, Y.; Bruyère, O.; Cederholm, T.; Cooper, C.; Landi, F.; Rolland, Y.; Sayer, A.A.; et al. Sarcopenia: Revised European consensus on definition and diagnosis. In Age and Ageing; Oxford University Press: Oxford, UK, 2019; Volume 48, pp. 16–31.
  19. Shimabukuro, M. Leptin resistance and lipolysis of white adipose tissue: An implication to ectopic fat disposition and its consequences. In Journal of Atherosclerosis and Thrombosis; Japan Atherosclerosis Society: Tokyo, Japan, 2017; Volume 24, pp. 1088–1089.
  20. Fang, H.; Judd, R.L. Adiponectin regulation and function. Compr. Physiol. 2018, 8, 1031–1063.
  21. Wu, H.; Ballantyne, C.M. Skeletal muscle inflammation and insulin resistance in obesity. J. Clin. Investig. 2017, 127, 43–54.
  22. Chait, A.; den Hartigh, L.J. Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. Front. Cardiovasc. Med. 2020, 7, 22.
  23. Frontera, W.R.; Rodriguez Zayas, A.; Rodriguez, N. Aging of Human Muscle: Understanding Sarcopenia at the Single Muscle Cell Level. Phys. Med. Rehabil. Clin. N. Am. 2012, 23, 201–207.
  24. Colaianni, G.; Cinti, S.; Colucci, S.; Grano, M. Irisin and musculoskeletal health. In Annals of the New York Academy of Sciences; Blackwell Publishing Inc.: Hoboken, NJ, USA, 2017; Volume 1402, pp. 5–9.
  25. Colaianni, G.; Cuscito, C.; Mongelli, T.; Pignataro, P.; Buccoliero, C.; Liu, P.; Lu, P.; Sartini, L.; Comite, M.D.; Mori, G.; et al. The myokine irisin increases cortical bone mass. Proc. Natl. Acad. Sci. USA 2015, 112, 12157–12162.
  26. D’Antona, G.; Pellegrino, M.A.; Adami, R.; Rossi, R.; Naccari Carlizzi, C.; Canepari, M.; Saltin, B.; Bottinelli, R. The effect of ageing and immobilization on structure and function of human skeletal muscle fibres. J. Physiol. 2003, 552, 499–511.
  27. Burnstock, G.; Dale, N. Purinergic signalling during development and ageing. In Purinergic Signalling; Kluwer Academic Publishers: Amsterdam, The Netherlands, 2015; Volume 11, pp. 277–305.
  28. Zimmermann, H.; Zebisch, M.; Sträter, N. Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signal. 2012, 8, 437–502.
  29. Orriss, I.R.; Key, M.L.; Hajjawi, M.O.R.; Arnett, T.R. Extracellular ATP Released by Osteoblasts Is A Key Local Inhibitor of Bone Mineralisation. PLoS ONE 2013, 8, e69057.
  30. Orriss, I.R. The role of purinergic signalling in the musculoskeletal system. In Autonomic Neuroscience: Basic and Clinical; Elsevier: Amsterdam, The Netherlands, 2015; Volume 191, pp. 124–134.
  31. Buckley, K.A.; Hipskind, R.A.; Gartland, A.; Bowler, W.B.; Gallagher, J.A. Adenosine triphosphate stimulates human osteoclast activity via upregulation of osteoblast-expressed receptor activator of nuclear factor-κB ligand. Bone 2002, 31, 582–590.
  32. Wesselius, A.; Bours, M.J.L.; Agrawal, A.; Gartland, A.; Dagnelie, P.C.; Schwarz, P.; Jorgensen, N.R. Role of purinergic receptor polymorphisms in human bone. Front. Biosci. 2011, 16, 2572–2585.
  33. Jørgensen, N.R.; Husted, L.B.; Skarratt, K.K.; Stokes, L.; Tofteng, C.L.; Kvist, T.; Jensen, J.E.B.; Eiken, P.; Brixen, K.; Fuller, S.; et al. Single-nucleotide polymorphisms in the P2X7 receptor gene are associated with post-menopausal bone loss and vertebral fractures. Eur. J. Hum. Genet. 2012, 20, 675–681.
  34. Coccurello, R.; Volonté, C. P2X7 Receptor in the Management of Energy Homeostasis: Implications for Obesity, Dyslipidemia, and Insulin Resistance. Front. Endocrinol. 2020, 11, 199.
  35. Costa, M.A.; Barbosa, A.; Neto, E.; Sá-E-Sousa, A.; Freitas, R.; Neves, J.M.; Magalhães-Cardoso, T.; Ferreirinha, F.; Correia-De-Sá, P. On the role of subtype selective adenosine receptor agonists during proliferation and osteogenic differentiation of human primary bone marrow stromal cells. J. Cell Physiol. 2011, 226, 1353–1366.
  36. Gnad, T.; Scheibler, S.; Kugelgen, I.V.; Scheele, C.; Kilic, A.; Glode, A.; Hoffmann, L.S.; Reverte-Salisa, L.; Horn, P.; Mutlu, S.; et al. Adenosine activates brown adipose tissue and recruits beige adipocytes via A2A receptors. Nature 2014, 516, 395–399.
  37. Tozzi, M.; Novak, I. Purinergic receptors in adipose tissue as potential targets in metabolic disorders. In Frontiers in Pharmacology; Frontiers Media S.A.: Lausanne, Switzerland, 2017; Volume 8.
  38. Noronha-Matos, J.B.; Coimbra, J.; Sá-e-Sousa, A.; Rocha, R.; Marinhas, J.; Freitas, R.; Guerra-Gomes, S.; Ferreirinha, F.; Costa, M.A.; Correia-de-Sá, P. P2X7-induced zeiosis promotes osteogenic differentiation and mineralization of postmenopausal bone marrow-derived mesenchymal stem cells. FASEB J. 2014, 28, 5208–5222.
  39. Pandolfi, J.; Ferraro, A.; Lerner, M.; Serrano, J.R.; Dueck, A.; Fainboim, L.; Arruvito, L. Purinergic signaling modulates human visceral adipose inflammatory responses: Implications in metabolically unhealthy obesity. J. Leukoc. Biol. 2015, 97, 941–949.
  40. Haussler, M.R.; Norman, A.W. Chromosomal receptor for a vitamin D metabolite. Proc. Natl. Acad. Sci. USA 1969, 62, 155–162.
  41. Kuchuk, N.O.; van Schoor, N.M.; Pluijm, S.M.; Chines, A.; Lips, P. Vitamin D status, parathyroid function, bone turnover, and BMD in postmenopausal women with osteoporosis: Global perspective. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 2009, 24, 693–701.
  42. McGill, A.T.; Stewart, J.M.; Lithander, F.E.; Strik, C.M.; Poppitt, S.D. Relationships of low serum vitamin D3 with anthropometry and markers of the metabolic syndrome and diabetes in overweight and obesity. Nutr. J. 2008, 7, 1–5.
  43. Bischoff, H.A.; Borchers, M.; Gudat, F.; Duermueller, U.; Theiler, R.; Stahelin, H.B.; Dick, W. In situ detection of 1,25-dihydroxyvitamin D3 receptor in human skeletal muscle tissue. Histochem. J. 2001, 33, 19–24.
  44. Lips, P.; Duong, T.U.; Oleksik, A.; Black, D.; Cummings, S.; Cox, D.; Nickelsen, T. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: Baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J. Clin. Endocrinol. Metab. 2001, 86, 1212–1221.
  45. Beaudart, C.; Zaaria, M.; Pasleau, F.; Reginster, J.Y.; Bruyère, O. Health outcomes of sarcopenia: A systematic review and meta-analysis. PLoS ONE 2017, 12, e0169548.
  46. Zhang, L.; Quan, M.; Cao, Z.B. Effect of vitamin D supplementation on upper and lower limb muscle strength and muscle power in athletes: A meta-analysis. PLoS ONE 2019, 14, e0215826.
  47. Thanapluetiwong, S.; Chewcharat, A.; Takkavatakarn, K.; Praditpornsilpa, K.; Eiam-Ong, S.; Susantitaphong, P. Vitamin D supplement on prevention of fall and fracture: A Meta-analysis of Randomized Controlled Trials. Medicine 2020, 99, e21506.
  48. Bouillon, R.; Marcocci, C.; Carmeliet, G.; Bikle, D.; White, J.H.; Dawson-Hughes, B.; Lips, P.; Munns, C.F.; Lazaretti-Castro, M.; Giustina, A.; et al. Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions. Endocr. Rev. 2019, 40, 1109.
  49. Soares, M.J.; Murhadi, L.L.; Kurpad, A.V.; Chan She Ping-Delfos, W.L.; Piers, L.S. Mechanistic roles for calcium and vitamin D in the regulation of body weight. Obes. Rev. 2012, 13, 592–605.
  50. Coskun, G.; Sencar, L.; Tuli, A.; Saker, D.; Alparslan, M.M.; Polat, S. Serum 25-hydroxyvitamin D level in relation to weight change and the risk of weight gain in adults of normal weight at baseline: The Norwegian HUNT cohort study. BMJ Open 2020, 10, e039192.
  51. Locke, A.E.; Kahali, B.; Berndt, S.I.; Justice, A.E.; Pers, T.H.; Day, F.R.; Powell, C.; Vedantam, S.; Buchkovich, M.L.; Yang, J.; et al. Genetic studies of body mass index yield new insights for obesity biology. Nature 2015, 518, 197–206.
  52. Pigeyre, M.; Yazdi, F.T.; Kaur, Y.; Meyre, D. Recent progress in genetics, epigenetics and metagenomics unveils the pathophysiology of human obesity. In Clinical Science; Portland Press Ltd.: London, UK, 2016; Volume 130, pp. 943–986.
  53. Kirk, B.; Zanker, J.; Duque, G. Osteosarcopenia: Epidemiology, diagnosis, and treatment—Facts and numbers. J. Cachexia Sarcopenia Muscle 2020, 11, 609–618.
  54. Li, S.; Chen, B.; Chen, H.; Hua, Z.; Shao, Y.; Yin, H.; Wang, J. Analysis of potential genetic biomarkers and molecular mechanism of smoking-related postmenopausal osteoporosis using weighted gene co-expression network analysis and machine learning. PLoS ONE 2021, 16, e0257343.
  55. Zhu, X.; Bai, W.; Zheng, H. Twelve years of GWAS discoveries for osteoporosis and related traits: Advances, challenges and applications. Bone Res. 2021, 9, 23.
  56. Urzi, F.; Pokorny, B.; Buzan, E. Pilot Study on Genetic Associations with Age-Related Sarcopenia. Front. Genet. 2020, 11, 615238.
  57. Jin, Y.; Kim, D.; Choi, Y.J.; Song, I.; Chung, Y.S. Gene Network Analysis for Osteoporosis, Sarcopenia, Diabetes, and Obesity in Human Mesenchymal Stromal Cells. Genes 2022, 13, 459.
  58. Bocheva, G.; Slominski, R.M.; Slominski, A.T. The Impact of Vitamin D on Skin Aging. Int. J. Mol. Sci. 2021, 22, 9097.
  59. Bischoff-Ferrari, H.A.; Borchers, M.; Gudat, F.; Dürmüller, U.; Stähelin, H.B.; Dick, W. Vitamin D Receptor Expression in Human Muscle Tissue Decreases with Age. J. Bone Miner. Res. 2004, 19, 265–269.
  60. Alalwan, T.A. Phenotypes of sarcopenic obesity: Exploring the effects on peri-muscular fat, the obesity paradox, hormone-related responses and the clinical implications. Geriatrics 2020, 5, 8.
  61. Noronha-Matos, J.B.; Correia-de-Sá, P. Mesenchymal Stem Cells Ageing: Targeting the "Purinome" to Promote Osteogenic Differentiation and Bone Repair. J. Cell Physiol. 2016, 231, 1852–1861.
  62. Snijders, T.; Parise, G. Role of muscle stem cells in sarcopenia. Curr. Opin. Clin. Nutr. Metab. Care 2017, 20, 186–190.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Medicine, General & Internal
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Nektaria Papadopoulou-Marketou
,
Anna Papageorgiou
,
George P. Chrousos
View Times: 191
Revisions: 2 times (View History)
Update Date: 05 Jun 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback